0001209191-23-052687.txt : 20231012 0001209191-23-052687.hdr.sgml : 20231012 20231012160010 ACCESSION NUMBER: 0001209191-23-052687 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231011 FILED AS OF DATE: 20231012 DATE AS OF CHANGE: 20231012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Delfini Lisa CENTRAL INDEX KEY: 0001873253 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38886 FILM NUMBER: 231322714 MAIL ADDRESS: STREET 1: C/O TREVI THERAPEUTICS, INC. STREET 2: 195 CHURCH STREET, FL. 14 CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Trevi Therapeutics, Inc. CENTRAL INDEX KEY: 0001563880 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 450834299 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 195 CHURCH STREET STREET 2: 14TH FLOOR CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-304-2499 MAIL ADDRESS: STREET 1: 195 CHURCH STREET STREET 2: 14TH FLOOR CITY: NEW HAVEN STATE: CT ZIP: 06510 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-11 0 0001563880 Trevi Therapeutics, Inc. TRVI 0001873253 Delfini Lisa C/O TREVI THERAPEUTICS, INC. 195 CHURCH STREET, 16TH FLOOR NEW HAVEN CT 06510 0 1 0 0 Chief Financial Officer 1 Common Stock 2023-10-11 4 M 0 2292 0.511 A 36686 D Common Stock 2023-10-11 4 S 0 785 2.02 D 35901 D Stock Option (right to buy) 0.511 2023-10-11 4 M 0 2292 0.00 D 2032-02-10 Common Stock 2292 64168 D This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022. This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on October 11, 2023. This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. /s/ Christopher Galletta, attorney-in-fact 2023-10-12